Immune Checkpoint Inhibitor-Associated Myocarditis

Oncologist

Volumn 23, Issue 8, 2018, Pages 879-886

  Ganatra, Sarju ^a   Neilan, Tomas G ^b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CD3 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TROPONIN I;

ADULT; ARTICLE; CARDIOMEGALY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSPNEA; ELECTROCARDIOGRAM; ENDOCARDIAL BIOPSY; FEMALE; HEART CATHETERIZATION; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG CONGESTION; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SINUS TACHYCARDIA; ADVERSE EVENT; IMMUNOTHERAPY; PATHOLOGY; RISK FACTOR;

ADULT; FEMALE; HUMANS; IMMUNOTHERAPY; MYOCARDITIS; RISK FACTORS;

EID: 85047658967     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2018-0130     Document Type: Article

References (43)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723
2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–2526
3. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–168
4. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016;44:51–60
5. Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755
6. Mahmood SS, Fradely MG, Cohen JV et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am College Cardiol 2018;71:1755–1764
7. Escudier M, Cautela J, Malissen N et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 2017;136:2085–2087
8. Wang DY, Okoye GD, Neilan TG et al. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep 2017;19:21
9. Berg DD, Vaduganathan M, Nohria A et al. Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail 2017;19:682–685
10. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer 2017;123:1904–1911
11. Johnson DB, Sullivan RJ, Ott PA et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016;2:234–240
12. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2016;27:1362
13. Norwood TG, Westbrook BC, Johnson DB et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 2017;5:91
14. Reuben A, Petaccia de Macedo M, McQuade J et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 2017;6:e1361097
15. Love VA, Grabie N, Duramad P et al. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res 2007;101:248–257
16. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319–322
17. Okazaki T, Tanaka Y, Nishio R et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003;9:1477–1483
18. Grabie N, Gotsman I, DaCosta R et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 2007;116:2062–2071
19. Nakashima H, Honda Y, Katayama T. Serial electrocardiographic findings in acute myocarditis. Intern Med 1994;33:659–666
20. Testani JM, Kolansky DM, Litt H et al. Focal myocarditis mimicking acute ST-elevation myocardial infarction: Diagnosis using cardiac magnetic resonance imaging. Tex Heart Inst J 2006;33:256–259
21. Deluigi CC, Ong P, Hill S et al. ECG findings in comparison to cardiovascular MR imaging in viral myocarditis. Int J Cardiol 2013;165:100–106
22. Abrar S, Ansari MJ, Mittal M et al. Predictors of mortality in paediatric myocarditis. J Clin Diagn Res 2016;10:SC12–SC16
23. Ogawa T, Veinot JP, Kuroski de Bold ML et al. Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis. Am J Physiol Heart Circ Physiol 2008;294:H2596–H2603
24. Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009;53:1475–1487
25. Farhad H, Staziaki PV, Addison D et al. Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2016;9
26. Mahrholdt H, Goedecke C, Wagner A et al. Cardiovascular magnetic resonance assessment of human myocarditis: A comparison to histology and molecular pathology. Circulation 2004;109:1250–1258
27. Abdel-Aty H, Boye P, Zagrosek A et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: Comparison of different approaches. J Am Coll Cardiol 2005;45:1815–1822
28. Grani C, Eichhorn C, Biere L et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol 2017;70:1964–1976
29. Aquaro GD, Perfetti M, Camastra G et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study. J Am Coll Cardiol 2017;70:1977–1987
30. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: Implications for role of sampling error. Mayo Clin Proc 1989;64:1235–1245
31. Maisch B, Portig I, Ristic A et al. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz 2000;25:200–209
32. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–1703
33. Suozzi KC, Stahl M, Ko CJ et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2016;2:264–268
34. Kwon HJ, Cote TR, Cuffe MS et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807–811
35. Rodriguez ER, Skojec DV, Tan CD et al. Antibody-mediated rejection in human cardiac allografts: Evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005;5:2778–2785
36. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011;30:252–269
37. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377–1386
38. Santini FC, Rizvi H, Wilkins O et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol 2017;35(suppl 15):2012a
39. Schadendorf D, Wolchok JD, Hodi FS et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. J Clin Oncol 2017;35:3807–3814
40. Menzies AM, Johnson DB, Ramanujam S et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017;28:368–376
41. Pollack MH, Betof A, Dearden H et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018;29:250–255
42. Armenian SH, Lacchetti C, Barac A et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017;35:893–911
43. Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 2018;29:84–91